About Michael Silber

This author has not yet filled in any details.
So far Michael Silber has created 2118 blog entries.

Virginia

Pharmacy made tremendous advances in the Commonwealth in the 2023 Regular Legislative Session that will dramatically improve patient care and advance practice. HB 2274, allowing pharmacists to test and treat for flu, COVID, strep and UTIs (urinary tract infections) under a statewide Board of Pharmacy protocol, is on Governor’s desk for signing, along with its companion, SB 948. The bills are the final piece in updating Virginia’s law to match the PREP Act. Notably, the Legislature also passed SB 1538 to clarify that Medicaid must reimburse for all the pharmacy-based services currently authorized in the Commonwealth. The bill applies to both Fee-for–Service and Managed Care. NACDS thanks the Virginia Association of Chain Drug Stores (VACDS), the Virginia Pharmacists Association (VPhA) and members for their tremendous efforts on the ground during this short session. NACDS will continue to update members as the bill signing process unfolds.

For more information, contact NACDS’ Jill McCormack at 717-592-8977.

2023-03-03T10:03:10-05:00March 3, 2023|Virginia|

Washington

NACDS sponsored the Washington State Pharmacy Association’s successful Pharmacy Days at the Capitol on January 25 and February 13. More than 120 students and pharmacists participated in 60 appointments with legislators advocating for PBM reform and, in general, for the profession of pharmacy, promoting convenient access to healthcare services. Pharmacist James Lin from Kroger-QFC met with Sen. Javier Valdez (D).

For more information, contact NACDS’ Mary Staples at 817-442-1155.

2023-03-03T10:02:41-05:00March 3, 2023|Washington|

West Virginia

Our priority bills continue to advance in the Legislature. HB 2754, that would make the pharmacy immunization allowances from the federal PREP Act permanent in state law, was approved by the Senate Health and Human Resources Committee and is now on the Senate Floor for a final vote. The Senate passed an omnibus Rules package, SB 361, that authorizes the Board of Pharmacy to promulgate a rule increasing the pharmacy technician ratio from 1:4 to 1:6. The same bill also includes a final rule modernizing collaborative practice agreements to allow for population-based care. Notably, the collaborative practice rule is currently effective as an emergency rule. The package now awaits action in the House Judiciary Committee, as does Committee Substitute SB 345, a bill that would provide legislative approval of the PBM rule pursuant to the passage of HB 2263 of 2021.

For more information, contact NACDS’ Jill McCormack at 717-592-8977.

2023-03-03T10:02:09-05:00March 3, 2023|West Virginia|

Arizona

The Board of Pharmacy Task Force Committee-Rules Writing meeting will be held on February 22 at 9:00 a.m. An agenda has not been posted on the website.

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

2023-02-17T11:25:01-05:00February 17, 2023|Arizona|

California

The Department of Health Care Services posted the following alerts and weekly notices on the Medi-Cal Rx Web Portal. Please note the reinstatement resources and information below. 

Also in California, Medi-Cal posted the following:  

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

2023-02-17T11:24:35-05:00February 17, 2023|California|

Indiana

The Family and Social Services Administration (FSSA) posted several bulletins of interest to pharmacies. 

  • BT202306 – Pharmacy updates approved by Drug Utilization Review Board January 2023 
  • BT202304 – IHCP [Indiana Health Coverage Programs] announces end to member continuous eligibility 
  • BT2022118 – Pharmacy updates approved by Drug Utilization Review Board December 2022 

For more information, contact NACDS’ Mary Staples at 817-442-1155.

2023-02-17T11:23:23-05:00February 17, 2023|Indiana|

Iowa

The Board of Pharmacy announced the following effective March 15: 

  • ARC 6843C has been adopted and amends Chapter 10, “Controlled Substances” placing one substance into Schedule I of the Iowa Controlled Substances Act (CSA) in alignment with . 
  • ARC 6844C has been adopted and amends Chapter 37, “Iowa Prescription Monitoring Program” establishing council membership information for the PMP Advisory Council and clarifying that only overdoes-reversal opioid antagonists are required to be submitted to the PMP.  

Also in Iowa, the Board of Pharmacy issued a “Notice of Intended Action” related to ARC 6874C amending Chapter 10, “Controlled Substances,” and Chapter 12, “Precursor Substances.” This proposed rulemaking temporarily adds four substances to Schedule I, excludes one substance from Schedule II and adds one substance as a precursor substance to the Iowa CSA in alignment with response to similar action taken by the DEA ARC 6874C amending Chapter 10, “Controlled Substances,” and Chapter 12, “Precursor Substances.” This proposed rulemaking temporarily adds four substances to Schedule I, excludes one substance from Schedule II and adds one substance as a precursor substance to the Iowa CSA in alignment with DEA’s action. Comments may be submitted until 4:30 p.m. on February 28. 

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

2023-02-17T11:22:49-05:00February 17, 2023|Iowa|

© National Association of Chain Drug Stores
All Rights Reserved | Privacy & Disclaimer

Go to Top